Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose lenvatinib plus b-TACE versus b-TACE for unresectable large hepatocellular carcinoma
ChiCTR2500098297Phase 3Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lenvatinib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: progression-free survival. Started Sep 2024; status: recruiting.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500098297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098297.